cardiovascular diseases
Fluicell's issuance will accelerate development of diabetes treatment
Fluicell develops tissue-based products with the goal of offering treatment alternatives for serious and incurable diseases such as type 1 diabetes, cardiovascular diseases and...
Cereno builds momentum for major clinical milestones
Cereno Scientific has announced clear progress in its...
CEO interview: Annette Colin Lövgren, Annexin Pharmaceuticals
Annexin Pharmaceuticals is developing a new biological drug based on Annexin A5,...